Prescient Therapeutics (ASX: PTX)
Live Investor Briefing
Please join Reach Markets Managing Director Patrick Nelson and Prescient Therapeutics CEO Steven Yatomi-Clarke for a special live investor briefing.
Event Details:
Register for an upcoming session
Event Topics:
- Moving the cancer conversation from “fight” to “cure” showing a 100% overall response rates as seen in a recent Johnson & Johnson trial;
- PTX’s relationship with the University of Pennsylvania, the minds behind the original CAR-T breakthrough;
- PTX’s goal of becoming the “Intel Inside” personalised cancer therapy, and more;
- How two of PTX’s assets have been chosen as part of a COVID-19 screen program.
This is a live and interactive session, you simply need an internet connection to participate. Don’t miss out, spots are limited – This is a FREE event.
Book Your Spot
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets have been engaged to help manage our investor communications.
What is a 708 investor?FEATURE SPEAKER
Steven Yatomi Clarke
CEO and Managing Director
Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.